| Document |
Document Title |
|
WO/2021/125493A1 |
Disclosed is a recombinant microorganism comprising a genetic modification that increases the activity of a multidrug transporter A (multidrug efflux system subunit A: MdtA). A recombinant microorganism comprising genetic modification th...
|
|
WO/2021/125867A1 |
The present application relates to a microorganism for producing a compound and a compound production method using same.
|
|
WO/2021/125494A1 |
The present invention relates to a multidrug efflux pump (mepA) variant, a polynucleotide that codes the variant, a microorganism comprising the variant, and a method for producing violacein or deoxyviolacein using same, the present inve...
|
|
WO/2021/125352A1 |
The present invention provides: a method for synthesizing celosianin II; a method for synthesizing betaxanthin; an amyloid-β polymerization inhibitor, or a therapeutic or prophylactic agent for Alzheimer's disease; an amyloid peptide ag...
|
|
WO/2021/119548A1 |
This disclosure concerns the metabolic engineering of microorganisms to provide biosynthetic methods for the production of insect pheromones and precursors thereof in a scalable and eco-friendly fermentation reaction; for example, by con...
|
|
WO/2021/110858A1 |
An enzyme-mediated method for the production of 3a-ethyl-6,6,9a-trimethyldodecahydronaphtho[2,1-b]furan, the products of said method, and uses of said products.
|
|
WO/2021/110848A1 |
Squalene Hopene Cyclase (SHC) enzymes and variants thereof and their uses for making (-)-Ambrox from homofarnesol and Ambra oxide from bishomofarnesol.
|
|
WO/2021/110992A1 |
The invention describes a non-naturally occurring bacteria modified genetically to produce tryptophan derived compounds including N,N-Dimethyltryptamine. The modified bacteria is preferably Escherichia coli or Zymomonas mobilis and it is...
|
|
WO/2021/103432A1 |
Provided is an alcohol dehydrogenase mutant that has high thermal stability and high catalytic efficiency and conversion efficiency for producing chiral bisaryl alcohol by asymmetrically reducing subchiral bisaryl ketone, and an applicat...
|
|
WO/2021/103863A1 |
Provided is a method for increasing the content of flavonoid phenylpropanoid compounds in Saussurea involucrata cell culture. A culture medium used in the present method comprises a phosphorus concentration of 0.5-3 mmol/L, a NO3-ion con...
|
|
WO/2021/108617A1 |
The invention relates to engineered microorganisms (e.g., E. coli) and associated improvements for increasing the production cannabinoids (e.g. CBGA) or precursors or derivatives thereof.
|
|
WO/2021/098593A1 |
The present invention relates to the technical field of natural medicine, and specifically relates to acquiring Secoemestrin C from microorganisms, particularly from fungal fermentation products, and the use of pharmaceutical salts there...
|
|
WO/2021/097452A2 |
The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin p...
|
|
WO/2021/092689A1 |
A method of culturing a photosynthetic microorganism comprising culturing the photosynthetic microorganism under a first light spectrum for a first period of time and under a second light spectrum for a second period of time. Further des...
|
|
WO/2021/089840A1 |
Described herein is a cost-effective method for fermentation of chalconoids in complex antimicrobial matrices originating from (spent) hops. A product is obtained which is highly enriched in certain phytoestrogens, in particular 8-prenyl...
|
|
WO/2021/081868A1 |
Disclosed is a mutant of nitrile hydratase derived from Caldalkalibacillus thermarum, which falls within the technical field of enzyme engineering. The half-life period of the nitrile hydratase mutant Cal.t Nhase-A20V provided in the pre...
|
|
WO/2021/081648A1 |
A genetically engineered microorganism for the production of a cannabinoid biosynthetic pathway product is described. The genetically engineered microorganism comprises at least one nucleic acid molecule encoding at least one cannabinoid...
|
|
WO/2021/081647A1 |
A genetically engineered microorganism for the production of a cannabinoid is described. The genetically engineered microorganism comprises at least one nucleic acid molecule encoding at least one cannabinoid biosynthetic pathway enzyme....
|
|
WO/2021/076629A1 |
The present invention is directed to a process for the synthesis of (1R, 4R, 5S)-4-(2- chloroethyl)-1-((S)-((S)-cyclohex-2-en-1-yl)(hydroxy)methyl)
-5-methyl-6-oxa-2- azabicyclo[3.2.0]heptane-3,7-dione; compound 1 (salinosporamide A, mar...
|
|
WO/2021/076638A1 |
The present invention relates to methods and transformed host cells for the production of eriodictyol from naringenin via bioconversion.
|
|
WO/2021/069714A1 |
The invention relate to genetically modified hosts cell comprising a pathway having enhanced production of one or more benzylisoquinoline alkaloids wherein the cell expresses heterologous insect genes encoding insect demethylases convert...
|
|
WO/2021/063396A1 |
Provided is various enzymes for cannabinoids synthesis and methods of making and using thereof. Also provided is the recombinant polypeptides having prenyl transferase activity and/or geranylpyrophosphate: olivatolate geranylttransfersae...
|
|
WO/2021/057913A1 |
Provided are a glycosyltransferase UGT76G1 mutant, an isolated polynucleotide, a carrier, a production method, and a composition and a kit for the glycosylation of substrates. Further provided are a method for increasing the catalytic ac...
|
|
WO/2021/058115A1 |
The present invention relates to a biocatalytical method for manufacturing of homoeriodictyol dihydrochalcone and/or hesperetin dihydrochalcone by providing at least one first biocatalyst system for the hydroxylation of phloretin and/or ...
|
|
WO/2021/058783A2 |
The present invention relates to a biocatalytical method for manufacturing of homoeriodictyol dihydrochalcone and/or hesperetin dihydrochalcone by providing at least one first biocatalyst system for the hydroxylation of phloretin and/or ...
|
|
WO/2021/053513A1 |
Genetically-modified cell comprising at least one heterologous polynucleotide encoding an enzyme involved in the flavonoid pathway. Method of making a flavonoid or flavonoid derivative in such a genetically-modified cell. Use of a flavon...
|
|
WO/2021/055597A1 |
The present disclosure provides engineered variants of a tetrahydrocannabinolic acid synthase (THCAS) polypeptide comprising an amino acid sequence of SEQ ID NO:44 with one or more amino acid substitutions, nucleic acids comprising nucle...
|
|
WO/2021/047566A1 |
Disclosed are a preparation method for a compound as shown in formula (I) and levo-praziquantel. A racemate of ester of the compound of formula (I) is used as a substrate, and reaction is performed under the catalysis of immobilized lipa...
|
|
WO/2021/050371A1 |
A recombinant microorganism includes a transgene encoding a polypeptide of a Type II biotin synthase, wherein a holo-protein of the Type II biotin synthase comprises per polypeptide chain a first [4Fe-4S] cluster (radical SAM (RS) cluste...
|
|
WO/2021/038095A1 |
The present invention relates to methods for the preparation of α-hydroxyacyl compounds, and peptides for the catalyzed formation of α-hydroxyacyl compounds as well as their use in the preparation of α-hydroxyacyl compounds.
|
|
WO/2021/035421A1 |
Provided is a folate producing strain and the preparation and application thereof, in particular, the expression level of the endogenous folCgene in the engineered strain of the present invention is decreased, and the exogenous folC gene...
|
|
WO/2021/036348A1 |
Provided is a folate producing strain and the preparation and application thereof, in particular, the expression level of the endogenous folC gene in the engineered strain of the present invention is decreased, and the exogenous folC gen...
|
|
WO/2021/037343A1 |
The invention relates to a cannabinoid concentrate and isolate with a high content of the acidic forms of the cannabinoids, method of obtaining the same and use thereof comprising providing a lipid extract using i.a. paraffin and subject...
|
|
WO/2021/034847A1 |
The present disclosure relates to the production of cannabinoids in either recombinant microorganism or in cell-free systems using a combination of enzymes, including but not limited to a PKS enzyme, a npgA enzyme, a cs-OLAS-1, a pp-DVAS...
|
|
WO/2021/034848A1 |
The disclosure relates to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro comprising the use of disclosed prenyltransferase variants.
|
|
WO/2021/018170A1 |
Provided are the preparation of a transformed microorganism for producing pyridine carboxamide with low by-product and the use thereof, wherein the preparation comprises the steps of construction of a plasmid with gene knockout, transfor...
|
|
WO/2021/015267A1 |
The present disclosure addresses the problem of providing an enzyme capable of dehydroxylating a hydroxyl group located at a specific position in a urolithin compound that has a hydroxyl group at at least the specific position. The probl...
|
|
WO/2021/004912A1 |
The invention relates to a Streptomyces clavuligerus strain comprising two point mutations in a ccaR promoter region and a substitution mutation in the ccaR gene, wherein the mutations in the ccaR promoter region are a C to T point mutat...
|
|
WO/2020/262107A1 |
The present invention relates to a production method of (R)-reticulin comprising: a step for obtaining a recombinant host cell by inserting, to a host cell, a gene 1 which is composed of a nucleotide sequence having at least 70% homology...
|
|
WO/2020/254745A1 |
The present invention relates to a selective process for the preparation of sulfones from sulfides by enzymatic catalysis, as well as to a composition comprising a symmetrical sulfide, an oxidoreductase enzyme catalyzing the oxidation of...
|
|
WO/2020/254744A1 |
The present invention relates to a selective process for preparing sulfoxides from sulfides by enzymatic catalysis, as well as to a composition comprising a symmetrical sulfide, wherein an oxidoreductase enzyme catalyzes the oxidation of...
|
|
WO/2020/247976A1 |
Provided herein are methods and compositions related to forming cross-links between surfactant molecules at an interface between dispersed phase partitions and a continuous phase in an emulsion, and uses of such cross-linked emulsions.
|
|
WO/2020/237552A1 |
Provided are a transaminase mutant and a method for producing chiral amines using the transaminase mutant. The amino acid sequence of the transaminase mutant is an amino acid sequence obtained after mutation occurs to the amino acid sequ...
|
|
WO/2020/233506A1 |
A method for improving the production of streptomyces polyketide compounds is provided. The method greatly improves the capability of the streptomyces polyketide compounds by strengthening a triacylglycerol decomposition pathway in strep...
|
|
WO/2020/232553A1 |
The present disclosure relates generally to methods and cell lines for the production of phytocannabinoids, phytocannabinoid precursors or intermediates, or phytocannabinoid analogue. Methods for transformation of host cells, such as yea...
|
|
WO/2020/234215A1 |
The present invention relates to a biological cell that can grow in the absence of biotin under aerobic conditions, comprising a BIO1 gene (i.e. CfBIO1), and preferably a BIO6, BIO2, BIO3, and BIO4 gene. The present disclosure additional...
|
|
WO/2020/229516A1 |
Herein are provided microbial factories, in particular yeast factories, for production of strictosidine aglycone and optionally other plant-derived compounds. Also provided are methods for producing strictosidine aglycone in a microorgan...
|
|
WO/2020/230833A1 |
The purpose of the present invention is to provide a novel compound which has the action of effectively enhancing the antifungal activity of an antifungal drug and which has a skeleton structure different from that of known pharmaceutica...
|
|
WO/2020/221795A1 |
The present invention relates to microbial factories, in particular yeast factories, for production of ergothioneine. Also provided are methods for producing ergothioneine in a yeast cell, as well as useful nucleic acids, polypeptides, v...
|
|
WO/2020/219859A1 |
Disclosed are trans-enoyl CoA reductase (TER) enzymes and nucleic acids encoding them. In some cases, the TER enzymes are non- natural, engineered trans-enoyl CoA reductase. TER enzymes were shown to catalyse the conversion of 5-carboxy-...
|
